From the bench to the bedside: The future of sepsis research - Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop

Chest

Volumn 111, Issue 3, 1997, Pages 744-753

  Dellinger, R P ^a   Opal, S M ^a   Rotrosen, D ^a   Suffredini, A F ^a   Zimmerman, J L ^a   Bone, R C ^a   Bosken, C H ^a   Goldstein, R A ^a   Hurd, S ^a   Vincent, J L ^a   Abraham, E ^a   Adams, H R ^a   Artigas, A ^a   Balk, R A ^a   Bernard, G R ^a   Bentler, B ^a   Cohen, J ^a   Cook, D J ^a   Danner, R L ^a   Dormski, P M ^a   Fisher, C J ^a   Fink, M P ^a   Glauser, M P ^a   Harkins, R ^a   Lauchenbruch, P ^a   Munford, R S ^a   Natanson, C ^a   Nelson, S ^a   Parrillo, J E ^a   Pennington, J E ^a   Roberts, R ^a   Sibhald, W J ^a   Siegel, J N ^a   Straube, R C ^a   Teres, D ^a   Ulevitch, R J ^a   Vogel, S ^a   Warren, S ^a   Wright, S D ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR;

CONFERENCE PAPER; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HOST RESISTANCE; INFLAMMATION; INTENSIVE CARE UNIT; MEDICAL SOCIETY; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; TISSUE INJURY;

EID: 2442729429     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.3.744     Document Type: Conference Paper

References (130)

1. Abraham E, Glauser MP, Gelmont D, et al. RO45-2081 (TNFR55-IgGI) in the treatment of patients' with severe sepsis/septic shock: preliminary results [abstract]. Proceedings of Second Annual Thematic Meeting on Sepsis; Deaville, France, 1995
2. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-n in patients with sepsis syndrome: a ramdomized, controlled, double-blind multicenter clinical trial. JAMA 1995; 27:5:934-41
3. Adams HR. Animal models that simulate circulatory shock in Immans: fact or fancy? Prog Clin Biol Res 1989; 299:241-42
4. Agosti JM, Fisher JC, Opal SM, et al. Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR) [abstract M3]. Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994; 65
5. Aiura K, Gelfand JA, Burke JF, et al. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun 1993; 61:3342-50
6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guideline's for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864
7. Babineau TJ, Marcello P, Swails W, et al. Raudomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994; 220:601-09
8. Bagby GJ, Plessala KJ, Wilson LA, et al. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-8
9. Bakker J, Zhang H. Depierreux M, et al. Effects of N-acetyleysteine in endotoxic shock. J Crit Care 1994; 9:236-43
10. d) macrophages. J Immunol 1995; 155:2303-05
11. Barber SA, Perera PY, McNally R, et al. The serine/threonine phosphatase inhibitor, calyeulin A inhibits and dissociates macrophage responses to lipopolysaccharide. J Immunol 1995; 155:1401-10
12. Barber SA, Salkowski CA, Fultz MJ, et al. Regulation of gene expression and nitric oxide production in murine macrophages by the serine/threonine phosphatase inhibitor okadaic acid. J Endotoxin Res 1996; 3:19-27
13. Barrie PS, Hydol J, Fischer E. A prospective comparison of two multiple organ dysfunction failure/scoring systems for prediction of mortality in critical surgical illness. J Trauma 1994; 37:660-66
14. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23:376-93
15. Baumgartner J-D, McCutchan JA, Melle GV, et al. Prevention of Gram negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; 13:59
16. Bernard GR. Sepsis trials: intersection of investigation, regulation, funding and practice. Am J Respir Crit Care Med 1995; 152:4-10
17. Berry DA. Experimental design for drug development: a Bayesian approach (review). J Biopharm Stat 1991; 1:81-101
18. Bhat NM, Bieber MM, Chapman CJ, et al. Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells. J Immunol 1993; 151:5011
19. Biros MH, Lewis RJ, Olson CM, et al. Informed consent in emergency research: consensus statement from the coalition conference of acute resuscitation and critical care researchers. JAMA 1995; 273:1283-87
20. Blanchard DK, Djen JY, Klein TW, et al. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukocyte Biol 1988; 43:429-35
21. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653
22. Boujoukos AJ, Martich GD, Supinski E, et al. Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration. J Appl Physiol 1993; 74: 3027-33
23. Braughler JM, Duncan LA, Chase HL. The involvement of iron in lipid peroxidation. J Biol Chem 1986; 261:10282-89
24. Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis 1986; 133:913-27
25. 2+ pump of the plasma membrane. J Biol Chem 1992; 267:2115-18
26. Casey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-78
27. Clapham DE. Calcium signaling. Cell 1995; 80:259-68
28. Cohen J. TNF and anti-TNF in sepsis: experimental basis of evaluation of new therapeutic approaches to sepsis. In: Vincent J-L, ed. Update in intensive care and emergency medicine No. 16. Berlin: Springer Verlag, 1992; 308-14
29. Cohen J, Carlet J, and the INTERSEPT Study Group. INTERSEPT: an international multicenter placebo controlled trial of monoclonal antibody to human TNF-alpha in patients with sepsis. Crit Care Med (in press)
30. Cross AS, Opal SM, Sadoff JD, et al. Choice of bacteria in animal models of sepsis. Infect Immun 1993; 61:2741-44
31. Cross AS, Opal SM, Palardy JE, et al. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993; 167:112-18
32. Chung IY, Kwon J, Benveniste EN. Role of protein kinase C activity in tumor necrosis factor-alpha gene expression: involvement at the transcriptioual level. J Immunol 1992; 149: 3894-3902
33. Dale DC, Liles WC, Summer WR, et al. Granulocyte colony-stimulating factor-role and relationship in infectious diseases. J Infect Dis 1995; 172:1061-75
34. Danner RL, Elin RJ, Hosseini JM, et al. Endotoxemia in human septic shock. Chest 1991; 99:169-75
35. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269:1829-35
36. Dybowski B, Cransden WR, Phillips I. Towards a statistically oriented decision support system for the management of septicemia. Artif Intell Med 1993; 5:489-502
37. Edwards FH, Albus BA, Zajtchuk R, et al. Use of a Bayesian statistical model for risk assessment in coronary artery surgery. Ann Thorac Surg 1988; 45:437-40
38. Eidelman RA, Sprung CL. Why have new effective therapies for sepsis not been developed? Crit Care Med 1994; 20:1330-34
39. Elebute EA, Stoner HB. The grading of sepsis. Br J Surg 1983; 70:29-31
40. Fisher CJ Jr, Opal SM, Dhainant JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis: the CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-27
41. Fisher E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-57
42. Fisher JC, Dhainaut JF, Opal SM, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with the sepsis syndrome - results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271:1836-43
43. Geppert TD, Whitehurst CE, Thompson P, et al. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the Ras/Raf-1/MEK/MAPK pathway. Mol Med 1994; 1:93-103
44. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 247:172-77
45. Granger DN, Hole of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 1988; 255:H1269-75
46. Granowitz EV, Santos AA, Poutsiska DD, et al. Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 1991; 338: 1423-24
47. Guidet B, Barakett V, Vassal T, et al. Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 1994; 106:1194-1201
48. Hadorn DC, Keeler KB, Rogers WH, et al. Recommendations of the Performance Statistics Subgroup. In: Assessing the performance of mortality prediction models. Santa Monica, Calif: Rand, 1993; 27-9
49. Hailman E, Lichenstein HS, Wurtel MM, et al. Lipopolysaccharide (LPS)-binding protein accelerates binding of LPS to CD14. J Exp Med 1994; 179:269-77
50. Hampton S. Problem solving in artificial neural networks (review). Prog Neurobiol 1994; 42:229-81
51. Han J, Lee JD, Tobias PS, et al. Endotoxin induces rapid protein tyrosine phosphorylation in 70/73 cells expressing CD14. J Biol Chem 1993; 268:25009-14
52. Han J, Lee JD, Bibbs L, et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265:808-11
53. Harris HW, Grunfeld C, Feingold KR, et al. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86:696-702
54. Harris HW, Grunfeld C, Feingold KR, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91:1028-31
55. Hata JS, Dellinger RP. Nitric oxide inhibition. Crit Care Med 1995; 23:1621-24
56. Haynes WC, Noon JP, Walker BR, et al. L-NMMA increases blood pressure in man. Lancet 1993; 342:931-32
57. d, macrophages. Mol Med 1995; 1:428-35
58. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990; 30:279-92
59. Hoffman WD, Danner RL, Ouezado ZMN, et al. Role of endotoxemia in cardiovascular dysfunction and lethality: virulent and nonvirulent Escherichia coli challenges in a canine model of septic shock. Infect Immun 1996; 64:406-12
60. Hubsch AP, Powell FS, Lerch PG, et al. A reconstituted apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23
61. Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction. Biochem J 1993; 291:329-43
62. Kanazawa M, Ishizaka A, Hasegawa N, et al. Granulocyte colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea pigs. Am Rev Respir Dis 1992; 145:1030-35
63. Knaus WA, Harrell FE, Fisher CJ, et al. The clinical evaluation of new drugs of sepsis: a prospective study design based on survival analysis. JAMA 1993; 270:1233-41
64. Knaus WA, Draper KA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29
65. Knaus WA, Harrell FE, Lynn J, et al. The SUPPORT prognostic model: objective estimate for survival for seriously ill hospitalize adults: study to understand prognoses and preferences for outcomes and risks. Ann Intern Med 1995; 122:191-203
66. Knaus WA, Wagner DP, Draper KA, et al. The APACHE III prognostic system risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-36
67. Knaus WA, Harrell FE, Fisher CJ, et al. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA 1993; 270:1233-41
68. Kolesnick H, Colde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77: 325-28
69. Kolls JK, Lei D, Nelson S, et al. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995; 171:570-75
70. Koyama S, Kobayshi T, Kubo K, et al. Recombinant-human superoxide dismutase attenuates endotoxin-induced lung injury in awake sheep. Am Rev Respir Dis 1992; 145:1404-09
71. Kramer RM, Roberts EF, Strifler BA, et al. Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 1995; 270:27395-98
72. Kretzschmar M. Role of oxygen free radicals in the pathophysiology of sepsis. In: Reinhart K, Eyrich K, Sprung C, eds. Sepsis: current perspectives in pathophysiology and therapy: update in intensive care and emergency medicine No. 18. Berlin: Springer-Verlag, 1994; 122-35
73. Le Gall JR, Lemeshow S, Huillard J, et al. Customized probability models for early sepsis in adult intensive care patients. JAMA 1995; 273:644-50
74. Le Gall JK, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63
75. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:739-46
76. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in development of logistic regression models. Am J Epidemiol 1982; 115:92-100
77. Lemeshow S, Teres D, Klar J. et al. Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993; 270:2478-86
78. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. PNAS 1993: 90:12040-44
79. Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995; 20:143
80. Marshall JC, Cook DJ, Christou NV, et al. The multiple organ dysfunction (MOD) score, a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-52
81. McCabe WR, Olans RN. Shock in Gram negative bacteremia: predisposing factors, pathophysiology, and treatment. In: Remington JS, Swartz WN, eds. Current clinical topics in infectious diseases (vol 2), New York: McGraw-Hill. 1981; 121-50
82. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with a human monoclonal antibody HAIA: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:1-5
83. 2 and antioxidants have opposite effects on activation of NF-n B and AP-1 in intact cells: AP-1 as a secondary antioxidant-responsive factor. EMBO J 1993; 12:2005-15
84. Moneada S, Higgs A. The L-arginine nitric oxide pathway. N Engl J Med 1993; 329:2002-12
85. Murata M, Monden M, Umeshita K, et al. Role of intracellular calcium in superoxide-induced hepatocyte injury. Hepatology 1993; 19:1223-28
86. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56:2563-69
87. Natanson C, Hoffman WD, Suffredini AF, et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-83
88. Nelson S, Bagby GJ, Bainton BG, et al. Compartmentalization of intra-alveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989; 159:189-94
89. News release (fax, July 18, 1994, Synergen: Boulder, Colo)
90. Opal SM. Lessons learned from clinical trials of sepsis. J Endotoxin Res 1995; 2:221-26
91. Novogrodsky A, Vanichkin A, Patya M, et al. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 1994; 264:1319-22
92. Overdahl MC, Julian MS, Weisbrode SK, et al. Fara-amino salicylate blocks the endothelial injury induced by phorbol myristate acetate. Am J Respir Crit Care Med 1994; 149: 1640-47
93. Pahl HL, Baeuerle PA. Oxygen and the control of gene expression. Bioessays 1994; 16:497-502
94. Palmer RMJ. The discovery of nitric oxide in the vessel wall: a unifying concept in the pathogenesis of sepsis. Arch Surg 1993; 128.396-401
95. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338:1557-58
96. Polk HC, Cheadle WG, Livingston DH, et al. A randomized prospective clinical trial to determine the efficacy of interferon-n in severely injured patients. Am J Surg 1992; 163:191-96
97. Preiser JC, Lejenne P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995; 23:259-64
98. Quezado ZMN, Hoffman WD, Winkelstein JA, et al. The third component of complement protects against Esceherichia coli endotoxin-induced shock and multiple organ failure. J Exp Med 1994; 179:569-78
99. Raingeaud J, Gupta S, Rogers JS, et al. Pro-inflammatory cytokines and environmental stress cause p38 MAP kinase activation by dual phosphorylation on lyrosine and threonine. J Biol Chem 1995; 270:7420-26
100. Rangel-Fransto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995; 273:117
101. Reinhart K. Wiegand-Löhnert C. Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study, Crit Care Med 1996; 24:733-42
102. Rodeheaver DP, Schnellman RG. Extracellular acidosis ameliorates metabolic-inhibitor-indunced and potentiates oxidant-induced cell death in renal proximal tubules. J Pharmacol Exp Ther 1993; 265:1355-60
103. Rossler OE, Rossler R. Chaos in physiology (review). Integr Physiol Behav Sci 1994; 29:328-33
104. Schumann RK, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429-30
105. Seekamp A, LaLonde C. Zhu DG, et al. Catalase prevents prostanoid release and lung lipid peroxidation after endotoxemia in sheep. J Appl Physiol 1988; 65:1210-16
106. Sibbald WJ, Vincent JL. Roundtable conference on clinical trials for the treatment of sepsis. Chest 1995; 107:522-27
107. Smedira NG, Evans BH, Grais LS, et al. Withholding and withdrawal of support from the critically ill. N Engl J Med 1990; 322:309-15
108. Sprung CL, Cohen J, Eidelman LA. A plea for caution in the performance of sepsis trials. Intensive Care Med 1995; 21:389-90
109. St. John BC, Dorinsky PM. Multiple organ dysfunction syndrome: pathogenesis and approach to therapy. Semin Respir Crit Care Med 1994; 15:325-34
110. Stevens JH, O'Hanley P, Shapiro JM, et al. Effect of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986; 77:1812-16
111. Suffredini AF. Current prospects for the treatment of clinical sepsis. Crit Care Med 1994; 22:S12
112. Terashima T, Kanazawa M, Sayama K, et al. Granulocyte colony stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs. Am J Respir Crit Care Med 1994; 149:1295-1303
113. Tite JP, Dougan C, Chatfield SN. The involvement of tumor necrosis factor in immunity to Salmonella infection. J Immunol 1991; 147:3161-64
114. Tobias P, Soldau K, Ulevitch B. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986; 164:777-93
115. Trede NS, Castigli E, Gelia HS, et al. Microbial superantigens induce NK-n B in the human monocytic cell line THP-1. J Immunol 1993; 150:5604-10
116. Ulevitch HJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 1994; 6:125-30
117. Ulevitch BJ, Tobias PS. Receptor-dependant mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13:437-57
118. Vallance P, Moncada S. Role of endogenous nitric oxide in septic shock. New Horizons 1993; 1:77-86
119. Varley AW, Coulthard MG, Meidell RS, et al. Inflammation-induced recombinant protein expression in vivo using promoters from acute phase protein genes. Proc Natl Acad Sci USA 1995; 92:5346
120. Wakabayashi G, Gelfand JA, Burke JF, et al. A specific receptor antagonist for interleukin-1 prevents Escherichia coli induced shock in rabbits. FASEB J 1991; 5:338-43
121. Watson C, Donaldson J, Grover R, et al. The cardiopulmonary effects of 546C88 in human septic shock. Intensive Care Med 1995; 21:S17
122. Weinstein DL, Lissner CR, Swanson RN, et al. Macrophage defect and inflammatory cell recruitment dysfunction in Salmonella susceptible C3II/HeJ mice. Cell Immunol 1986; 102:68-77
123. Weinstein SL, Sanghera JS, Lemke K, et al. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinase in macrophages. J Biol Chem 1992; 267:14955-62
124. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding proteins. Science 1990; 249:1431-33
125. Wright SD. CD14 and innate recognition of bacteria. J Immunol 1995; 155:6-8
126. Würfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181:1743-45
127. Wurfel MM, Kunitake ST, Lichenstein HS, et al. Lipopolysaccharide (LPS) binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994, 180:1025-35
128. Zanetti C, Hemmann D, Gerain J, et al. Cytokine production after intravenous or peritoneal Gram negative bacterial challenge in mice: comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol 1992; 148:1890-97
129. Zhang S, Han J, Sells MA, et al. Rho family GTPases regulate p38 MAP kinase through the downstream mediator Pakl. J Biol Chem 1995; 270:23934-36
130. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of Gram negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-30